• BIA Blog

CEO Update | 29 November 2021

I’m delighted to finally be able to leave the house today after my period of isolation after a positive COVID-19 test. It was such a shame not to be able to join our bioprocessing community last week for the 18th annual bioProcess UK conference but I have been enjoying looking at the photos from this great event. News over the weekend of the Omnicron variant has led to the postponement of the WTO Ministerial meeting in Geneva where waivers on the IP of COVID-19 vaccines were to be discussed, so I’m no longer expecting to see global policy set in Geneva this week.

How science prepares us for pandemic challenges

Antimicrobial resistance is a disaster waiting to happen, we must build our arsenal to combat it.

Guest blog: State of the UK cell and gene therapy industry in 2021

Despite the pandemic the cell and gene therapy industry in the UK has had another year of significant growth. The Cell and Gene Therapy Catapult has assessed the UK landscape in terms of investment, jobs and manufacturing capabilities and space. The organisation has published two 2021 reports, one focused on skills demand and one on GMP manufacturing.

Interview with Dr. Roumen Kofinov, General Manager of BB-NCIPD Ltd (Bul Bio) & Özgür Tuncer, CEO & Executive Director Stablepharma Ltd

An interview with BB-NCIPD Ltd (Bul Bio) & Özgür Tuncer, CEO & Executive Director Stablepharma Ltd highlights that the two companies have entered into a partnership to produce the world’s first fridge-free Tetanus diphtheria vaccine.

Guest blog: The Unified Patent Court (UPC) – now a real prospect

Tim Powell, Partner at Powell Gilbert LLP and member of the BIA’s Intellectual Property Advisory Committee (IPAC), talks about the Unified Patent Court becoming a real prospect in 2022.

CEO Update | 22 November 2021

I’m really disappointed that a positive COVID test and self isolation period means I will miss both bioProcessUK conference and the official opening of AstraZeneca’s R&D HQ in Cambridge this week - two events I was really looking forward to. I do plan to participate in the UK Government's Life Science Council as it is a virtual meeting this time around.

Guest blog: World Antimicrobial Awareness Week

Deborah O’Neil, CEO of NovaBiotics, explains the importance of Antimicrobial Resistance (AMR) awareness and why it is a 'silent pandemic'. She discusses rethinking reimbursement models, funding innovation, and what the AMR landscape is looking like.

Guest Blog: Introduction to Technology Transfer

Jennifer Shi, Director of GenScript ProBio Antibody Manufacturing Department, talks about technology transfer in biologics manufacturing. The aim of technology transfer is to achieve the commercial objectives of a product by transferring the product and process knowledge between R&D and production, either within one production site or between two production sites. Technology transfer occurs throughout the life cycle of biotherapeutics, so it is important for any company.

Guest Blog: Phaim Pharma - World Diabetes Day

World Diabetes Day, held on November 14th each year, is the primary global awareness campaign drawing attention to issues of paramount importance to the diabetes world. Phaim Pharma is focused on developing therapeutics and diagnostics for autoimmune disease via Antigenic ImmuneModulation (AIM). They have a flagship product in Type 1 Diabetes Mellitus (T1DM) which has the potential to arrest the disease process and be preventative.

CEO Update | 15 November 2021

Thank you to everyone who joined us at the Babraham Research Campus in Cambridge last week. It was great to meet BIA members, local start-ups and academics to talk about collaboration. We raised the question of whether more or better collaborations are needed, and ultimately found that success lies in finding a common goal and sharing the benefits of your product.